Thursday, April, 18, 2019 08:42:14

ASLAN Pharmaceuticals reveals results from Phase 2 study of Varlitinib

The study shows improvement in PFS in patients treated with metastatic gastric cancer therapy varlitinib. Renowned clinical-stage biopharmaceutical firm, ASLAN Pharmaceuticals has recently announced an update on the global placebo-controlled phase 2 clinical study of varlitinib, as first-line therapy in metastatic gastric cancer patients, while …

CytoReason to collaborate with Pfizer on innovative drug discovery

The American company will be paying millions to CytoReason for its unparalleled models. CytoReason, the Israel based machine learning company, that is credited for developing immune system cell-centered models that necessarily aid in drug discovery, recently entered a collaboration with American pharmaceutical corporation, Pfizer Inc. …